Dymon Asia Capital Singapore PTE. LTD. Sells 14,100 Shares of IQVIA Holdings Inc. $IQV

Dymon Asia Capital Singapore PTE. LTD. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 84.9% during the fourth quarter, Holdings Channel reports. The firm owned 2,500 shares of the medical research company’s stock after selling 14,100 shares during the quarter. Dymon Asia Capital Singapore PTE. LTD.’s holdings in IQVIA were worth $564,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Eagle Rock Investment Company LLC grew its stake in IQVIA by 33.6% during the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after acquiring an additional 11,657 shares in the last quarter. EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in IQVIA in the 3rd quarter worth $7,368,000. AMG National Trust Bank bought a new position in shares of IQVIA during the 3rd quarter valued at about $3,713,000. Citigroup Inc. grew its position in shares of IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock valued at $173,830,000 after purchasing an additional 475,557 shares in the last quarter. Finally, Dana Investment Advisors Inc. increased its holdings in shares of IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock worth $30,401,000 after purchasing an additional 24,854 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on IQV shares. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. HSBC set a $210.00 price target on shares of IQVIA in a research note on Wednesday, June 3rd. Finally, Morgan Stanley set a $225.00 price objective on shares of IQVIA in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Stock Performance

NYSE:IQV opened at $181.10 on Friday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock’s fifty day moving average is $173.56 and its 200 day moving average is $193.68. The firm has a market capitalization of $30.23 billion, a PE ratio of 22.44, a PEG ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a fifty-two week low of $153.01 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.